Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Anthony Elias

Concepts (664)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
108
2024
2253
6.110
 Why?
Antineoplastic Combined Chemotherapy Protocols
96
2025
1692
4.130
 Why?
Sarcoma
33
2025
188
3.890
 Why?
Receptors, Estrogen
22
2021
436
2.330
 Why?
Triple Negative Breast Neoplasms
14
2024
202
2.280
 Why?
Receptor, ErbB-2
22
2024
341
2.040
 Why?
Hematopoietic Stem Cell Transplantation
36
2011
622
2.000
 Why?
Carcinoma, Small Cell
19
2003
172
1.720
 Why?
Soft Tissue Neoplasms
14
2022
115
1.590
 Why?
Carcinoma, Ductal, Breast
7
2018
83
1.500
 Why?
Neoadjuvant Therapy
17
2024
404
1.340
 Why?
Antineoplastic Agents
31
2023
2129
1.240
 Why?
Neoplasm Recurrence, Local
20
2022
1079
1.160
 Why?
Neoplasm Staging
35
2024
1389
1.060
 Why?
Receptors, Progesterone
13
2020
350
1.050
 Why?
Lung Neoplasms
38
2003
2526
1.020
 Why?
Combined Modality Therapy
52
2024
1236
1.010
 Why?
Doxorubicin
24
2025
362
1.010
 Why?
Biomarkers, Tumor
17
2022
1276
0.970
 Why?
Paclitaxel
14
2024
230
0.920
 Why?
Mastectomy
9
2018
137
0.910
 Why?
CTLA-4 Antigen
1
2025
99
0.910
 Why?
Bone Marrow Transplantation
27
1998
286
0.910
 Why?
Bone Neoplasms
7
2025
247
0.850
 Why?
Antibodies, Monoclonal, Humanized
10
2025
804
0.840
 Why?
Antineoplastic Agents, Alkylating
5
2018
73
0.750
 Why?
Female
168
2025
73304
0.740
 Why?
Receptors, Androgen
7
2018
150
0.730
 Why?
Disease-Free Survival
24
2023
686
0.720
 Why?
Humans
226
2025
137585
0.710
 Why?
Middle Aged
112
2025
33479
0.690
 Why?
Antineoplastic Agents, Hormonal
10
2018
161
0.670
 Why?
Maytansine
3
2021
16
0.660
 Why?
Liposarcoma
4
2023
27
0.660
 Why?
Adult
114
2025
37929
0.610
 Why?
Neoplasm Metastasis
23
2024
658
0.600
 Why?
Chemotherapy, Adjuvant
23
2023
389
0.590
 Why?
Dioxoles
2
2015
9
0.570
 Why?
Tetrahydroisoquinolines
2
2015
8
0.570
 Why?
Cyclophosphamide
31
2024
247
0.570
 Why?
Aged
65
2025
23961
0.530
 Why?
Ifosfamide
19
1998
37
0.520
 Why?
Androgen Receptor Antagonists
6
2021
34
0.520
 Why?
Phenylthiohydantoin
5
2017
42
0.520
 Why?
Dasatinib
1
2016
54
0.510
 Why?
Trastuzumab
10
2024
96
0.500
 Why?
Neoplasms, Hormone-Dependent
3
2012
38
0.480
 Why?
Treatment Outcome
43
2024
10811
0.470
 Why?
Drug Administration Schedule
24
2018
786
0.450
 Why?
Carboplatin
21
2016
144
0.450
 Why?
Estrogen Receptor alpha
5
2021
145
0.450
 Why?
Granulocyte Colony-Stimulating Factor
11
2002
74
0.450
 Why?
Carcinoma, Non-Small-Cell Lung
17
2001
1081
0.430
 Why?
Clinical Trials as Topic
19
2018
1050
0.420
 Why?
Estrogens
6
2018
367
0.400
 Why?
Dacarbazine
9
2018
98
0.390
 Why?
Survival Rate
19
2021
1972
0.370
 Why?
Tamoxifen
9
2018
202
0.370
 Why?
Neoplasms
20
2009
2671
0.370
 Why?
Survival Analysis
23
2010
1325
0.360
 Why?
Prognosis
22
2021
4030
0.350
 Why?
Venous Thromboembolism
3
2020
316
0.350
 Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2013
976
0.350
 Why?
Pyrimidines
3
2020
470
0.350
 Why?
Programmed Cell Death 1 Receptor
2
2025
249
0.350
 Why?
Carcinoma, Intraductal, Noninfiltrating
3
2022
56
0.340
 Why?
Neoplasms, Second Primary
3
2022
118
0.340
 Why?
Antibodies, Monoclonal
9
2024
1430
0.340
 Why?
Dose-Response Relationship, Drug
17
2017
2057
0.330
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
8
1999
152
0.330
 Why?
Taxoids
7
2023
102
0.330
 Why?
Remission Induction
16
2002
288
0.320
 Why?
Breast Neoplasms, Male
3
2018
29
0.320
 Why?
Drug Resistance, Neoplasm
7
2017
801
0.310
 Why?
Gene Expression Regulation, Neoplastic
11
2018
1396
0.300
 Why?
Neoplastic Cells, Circulating
2
2020
80
0.290
 Why?
Mesna
12
1998
16
0.290
 Why?
Sarcoma, Ewing
3
2022
97
0.270
 Why?
Leiomyosarcoma
2
2018
28
0.270
 Why?
Cisplatin
14
2000
320
0.260
 Why?
Immunoconjugates
3
2024
114
0.260
 Why?
Sternum
1
2006
24
0.260
 Why?
Tumor Microenvironment
4
2024
674
0.250
 Why?
Immunohistochemistry
5
2016
1738
0.250
 Why?
Mastectomy, Segmental
2
2009
93
0.240
 Why?
Pyridines
2
2025
506
0.240
 Why?
Chondrosarcoma
1
2025
16
0.240
 Why?
Peripheral Blood Stem Cell Transplantation
2
2002
24
0.230
 Why?
Carcinoma, Ductal
1
2005
11
0.230
 Why?
Transplantation, Autologous
19
2002
238
0.230
 Why?
Melphalan
10
2002
35
0.230
 Why?
Male
66
2025
67762
0.230
 Why?
Isocitrate Dehydrogenase
1
2025
59
0.230
 Why?
Protein Kinase Inhibitors
4
2019
916
0.230
 Why?
Cell Adhesion Molecules
2
2021
181
0.230
 Why?
Lymph Nodes
1
2007
491
0.230
 Why?
Carcinoma
2
2008
240
0.220
 Why?
Glycine
1
2025
176
0.220
 Why?
Risk Reduction Behavior
2
2016
220
0.220
 Why?
Drug Evaluation
19
1998
84
0.220
 Why?
Adjuvants, Immunologic
3
2022
226
0.210
 Why?
Deoxycytidine
4
2020
179
0.210
 Why?
Ribonuclease III
2
2016
40
0.210
 Why?
Ovarian Neoplasms
3
2022
565
0.210
 Why?
Hodgkin Disease
4
2016
138
0.210
 Why?
Survivors
3
2016
493
0.210
 Why?
Thiotepa
13
2002
20
0.210
 Why?
Alkylating Agents
3
2000
24
0.200
 Why?
Triazoles
2
2022
147
0.200
 Why?
DEAD-box RNA Helicases
2
2016
76
0.200
 Why?
Aged, 80 and over
14
2021
7635
0.200
 Why?
Weight Loss
4
2016
787
0.200
 Why?
Behavior Therapy
2
2016
264
0.200
 Why?
Medical Oncology
5
2024
289
0.200
 Why?
Employment
1
2024
178
0.190
 Why?
Gene Expression Profiling
6
2017
1774
0.190
 Why?
Disease Management
5
2020
628
0.190
 Why?
Overweight
3
2016
558
0.190
 Why?
Obesity
4
2018
2992
0.190
 Why?
Mutation
4
2025
3958
0.190
 Why?
Salvage Therapy
6
2010
142
0.190
 Why?
Circulating Tumor DNA
1
2022
34
0.190
 Why?
Hydrazines
1
2022
35
0.190
 Why?
Carcinoma in Situ
2
2012
49
0.190
 Why?
Etoposide
10
2001
158
0.180
 Why?
Referral and Consultation
1
2007
786
0.180
 Why?
Hematologic Diseases
6
2008
62
0.180
 Why?
Emergency Medicine
1
2024
226
0.180
 Why?
Tumor Cells, Cultured
9
2020
955
0.180
 Why?
Liposarcoma, Myxoid
1
2021
10
0.180
 Why?
Sarcoma, Synovial
1
2021
21
0.180
 Why?
Recombinant Fusion Proteins
1
2024
665
0.180
 Why?
Aromatase Inhibitors
4
2021
54
0.180
 Why?
Endpoint Determination
1
2021
77
0.170
 Why?
Sentinel Lymph Node Biopsy
3
2017
115
0.170
 Why?
Cancer Care Facilities
1
2020
38
0.170
 Why?
Indazoles
1
2020
69
0.170
 Why?
Leukocytes, Mononuclear
3
2020
558
0.170
 Why?
Time Factors
12
2020
6828
0.170
 Why?
Hematopoietic Stem Cells
5
1996
406
0.170
 Why?
Cell Separation
3
2017
318
0.170
 Why?
Diphosphonates
1
2020
66
0.160
 Why?
Pyrroles
2
2013
213
0.160
 Why?
Bone Marrow
8
2000
286
0.160
 Why?
Diet
3
2018
1278
0.160
 Why?
Nuclear Medicine
1
2019
9
0.150
 Why?
Antigens, Neoplasm
4
2021
319
0.150
 Why?
Hematology
1
2019
20
0.150
 Why?
Proportional Hazards Models
6
2020
1266
0.150
 Why?
Cell Line, Tumor
9
2017
3412
0.150
 Why?
MCF-7 Cells
5
2017
124
0.150
 Why?
Fluorouracil
7
2013
208
0.150
 Why?
CA-125 Antigen
2
2013
14
0.150
 Why?
Epithelial-Mesenchymal Transition
1
2020
209
0.150
 Why?
Thromboembolism
1
2019
119
0.140
 Why?
Nitriles
5
2017
172
0.140
 Why?
Pulmonary Medicine
1
2019
85
0.140
 Why?
Benzamides
5
2017
216
0.140
 Why?
Bayes Theorem
4
2024
405
0.140
 Why?
Receptor, Fibroblast Growth Factor, Type 1
1
2018
53
0.140
 Why?
Cyclin-Dependent Kinase 4
1
2018
47
0.140
 Why?
Cyclin-Dependent Kinase 6
1
2018
42
0.140
 Why?
Cell Cycle
1
2021
601
0.140
 Why?
Tissue Inhibitor of Metalloproteinase-3
1
2017
9
0.140
 Why?
Infusions, Intravenous
10
2020
413
0.140
 Why?
Kaplan-Meier Estimate
6
2018
889
0.140
 Why?
Research Design
3
2021
1139
0.140
 Why?
Indoles
2
2013
412
0.140
 Why?
Anesthesiology
1
2019
87
0.140
 Why?
Schwann Cells
1
2017
34
0.140
 Why?
Tetrahydronaphthalenes
1
2017
29
0.140
 Why?
Sciatic Nerve
1
2017
58
0.140
 Why?
Microbubbles
1
2017
49
0.140
 Why?
Valine
1
2017
82
0.130
 Why?
Vaccines
1
2022
406
0.130
 Why?
Societies, Medical
2
2019
820
0.130
 Why?
Betacoronavirus
1
2020
270
0.130
 Why?
Venous Thrombosis
1
2019
190
0.130
 Why?
Camptothecin
3
2024
116
0.130
 Why?
Lymph Node Excision
3
2015
171
0.130
 Why?
Amyloid Precursor Protein Secretases
1
2017
80
0.130
 Why?
Axilla
3
2017
47
0.130
 Why?
Sulfonamides
1
2020
513
0.130
 Why?
Immunotherapy
2
2018
641
0.130
 Why?
Androgen Antagonists
2
2015
82
0.130
 Why?
Cancer-Associated Fibroblasts
1
2016
20
0.130
 Why?
Gonadal Steroid Hormones
1
2018
140
0.130
 Why?
Internship and Residency
2
2024
1147
0.130
 Why?
Hematopoietic Cell Growth Factors
2
1995
4
0.130
 Why?
Ultrasonography, Mammary
1
2016
13
0.130
 Why?
Neoplasms, Germ Cell and Embryonal
2
1995
77
0.130
 Why?
Neoplasms, Radiation-Induced
1
2016
92
0.130
 Why?
Thiazoles
1
2016
123
0.120
 Why?
Follow-Up Studies
6
2025
5131
0.120
 Why?
Antibody Specificity
1
2016
189
0.120
 Why?
Lymphatic Metastasis
3
2017
352
0.120
 Why?
Ambulatory Care
1
2020
546
0.120
 Why?
Neoplasm Invasiveness
3
2016
510
0.120
 Why?
Tumor Suppressor Protein p53
2
2023
528
0.120
 Why?
Myelin Sheath
1
2017
167
0.120
 Why?
Maximum Tolerated Dose
1
2016
199
0.120
 Why?
Antibiotics, Antineoplastic
1
2016
127
0.120
 Why?
Neoplastic Stem Cells
2
2017
399
0.120
 Why?
Benzimidazoles
1
2016
170
0.120
 Why?
Quinolines
1
2016
178
0.120
 Why?
Pneumonia, Viral
1
2020
373
0.110
 Why?
Coronavirus Infections
1
2020
364
0.110
 Why?
Pyrazoles
1
2018
423
0.110
 Why?
Recurrence
5
2020
1060
0.110
 Why?
Mammography
1
2016
154
0.110
 Why?
Animals
17
2021
36940
0.110
 Why?
Drug Therapy, Combination
4
2014
1066
0.110
 Why?
Disease Progression
7
2018
2757
0.110
 Why?
Radiotherapy, Adjuvant
5
2016
220
0.110
 Why?
Homeodomain Proteins
2
2018
506
0.110
 Why?
Administration, Oral
4
2020
816
0.110
 Why?
Antibodies
1
2016
410
0.110
 Why?
Brain Edema
1
2014
61
0.110
 Why?
Hepatic Veno-Occlusive Disease
3
2002
14
0.110
 Why?
Young Adult
10
2025
13209
0.110
 Why?
Radiotherapy Dosage
3
1999
268
0.110
 Why?
TOR Serine-Threonine Kinases
1
2017
412
0.110
 Why?
Exercise
2
2015
2057
0.110
 Why?
Vascular Neoplasms
1
2013
18
0.110
 Why?
Clinical Trials, Phase I as Topic
3
2024
50
0.100
 Why?
Comorbidity
5
2017
1622
0.100
 Why?
Radiotherapy
3
2015
201
0.100
 Why?
Testicular Neoplasms
1
1995
110
0.100
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
3
2022
115
0.100
 Why?
Epigenesis, Genetic
2
2018
660
0.100
 Why?
Keratins
2
2017
173
0.100
 Why?
Cellular Reprogramming
1
2014
99
0.100
 Why?
Bridged-Ring Compounds
3
2020
14
0.100
 Why?
Mercaptoethanol
2
1990
11
0.100
 Why?
Mice
12
2021
17787
0.100
 Why?
Adenocarcinoma
6
2015
940
0.100
 Why?
Apoptosis
6
2023
2553
0.100
 Why?
Patient Selection
4
2016
696
0.100
 Why?
Gallium Radioisotopes
1
1992
14
0.100
 Why?
Cell Proliferation
6
2017
2475
0.100
 Why?
Bone Marrow Cells
4
2000
316
0.100
 Why?
Chromatin
1
2016
519
0.100
 Why?
Carmustine
10
2001
50
0.100
 Why?
Adolescent
23
2025
21513
0.100
 Why?
Protein-Tyrosine Kinases
2
2022
434
0.090
 Why?
Anthracyclines
3
2023
42
0.090
 Why?
Lymphoma, Non-Hodgkin
3
2001
87
0.090
 Why?
Methotrexate
4
2002
260
0.090
 Why?
Retrospective Studies
12
2023
15657
0.090
 Why?
Brain Neoplasms
5
2014
1238
0.090
 Why?
Weight Reduction Programs
1
2012
117
0.090
 Why?
Neoplasm, Residual
2
2022
133
0.090
 Why?
RNA, Catalytic
1
2012
187
0.090
 Why?
Radiosurgery
1
2014
344
0.090
 Why?
Polydeoxyribonucleotides
2
2002
14
0.090
 Why?
Risk Assessment
3
2020
3457
0.090
 Why?
Aorta
1
2013
417
0.090
 Why?
Neutropenia
5
2013
146
0.090
 Why?
Age Factors
5
2019
3295
0.090
 Why?
Carcinoma, Lobular
1
2011
49
0.090
 Why?
Neoplasm Grading
3
2017
307
0.080
 Why?
Multivariate Analysis
4
2013
1509
0.080
 Why?
Leukapheresis
4
2001
21
0.080
 Why?
Liver Neoplasms
3
2015
786
0.080
 Why?
Keratin-5
1
2010
50
0.080
 Why?
Angiogenesis Inhibitors
1
2012
229
0.080
 Why?
Biopsy
3
2018
1129
0.080
 Why?
Practice Patterns, Physicians'
1
2019
1313
0.080
 Why?
Molecular Targeted Therapy
3
2018
411
0.080
 Why?
Peptide Mapping
1
2010
64
0.080
 Why?
Electrophoresis, Gel, Two-Dimensional
1
2010
114
0.080
 Why?
Databases, Protein
1
2010
85
0.080
 Why?
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
1
2010
144
0.080
 Why?
Benzenesulfonates
1
2009
22
0.080
 Why?
Postmenopause
2
2017
366
0.080
 Why?
CD146 Antigen
2
2021
42
0.080
 Why?
Urinary Tract
1
1990
51
0.080
 Why?
BRCA2 Protein
1
2009
63
0.080
 Why?
Health Facilities
1
2009
84
0.080
 Why?
Pregnancy Complications, Neoplastic
1
2009
52
0.080
 Why?
Thrombophilia
1
2009
83
0.080
 Why?
Observer Variation
1
2010
343
0.080
 Why?
Patient Care
1
2009
111
0.070
 Why?
Risk Factors
8
2020
10388
0.070
 Why?
United States
9
2023
14841
0.070
 Why?
Perimenopause
1
2008
63
0.070
 Why?
Mice, Nude
3
2017
698
0.070
 Why?
Fibrinolytic Agents
2
2002
270
0.070
 Why?
Bone Marrow Diseases
4
2000
19
0.070
 Why?
In Situ Hybridization
2
2010
316
0.070
 Why?
Fatigue
3
2018
329
0.070
 Why?
In Situ Hybridization, Fluorescence
1
2008
317
0.070
 Why?
Randomized Controlled Trials as Topic
6
2000
1477
0.070
 Why?
Xenograft Model Antitumor Assays
3
2017
872
0.070
 Why?
Blotting, Western
1
2010
1226
0.070
 Why?
Pneumonectomy
3
1997
152
0.060
 Why?
Sputum
1
1988
311
0.060
 Why?
Reproducibility of Results
2
2016
3284
0.060
 Why?
Quality of Life
2
2015
2892
0.060
 Why?
Proto-Oncogene Proteins c-akt
2
2019
437
0.060
 Why?
Clinical Decision-Making
2
2020
322
0.060
 Why?
Neoplasm Proteins
2
2007
434
0.060
 Why?
Life Tables
2
2002
20
0.060
 Why?
Anilides
2
2016
73
0.060
 Why?
New Jersey
1
2024
14
0.060
 Why?
Positron-Emission Tomography
1
2006
294
0.060
 Why?
Colony-Stimulating Factors
3
1988
36
0.060
 Why?
Predictive Value of Tests
2
2016
2031
0.060
 Why?
Enzyme Inhibitors
1
2008
840
0.060
 Why?
Receptor, TIE-2
1
2024
12
0.050
 Why?
Granulocytes
4
1995
80
0.050
 Why?
Anticoagulants
2
2019
664
0.050
 Why?
New York
1
2024
126
0.050
 Why?
Genes, Neoplasm
1
2004
22
0.050
 Why?
Ricin
2
1997
8
0.050
 Why?
Oligonucleotide Array Sequence Analysis
3
2012
767
0.050
 Why?
Growth Substances
3
1988
147
0.050
 Why?
Patient Care Planning
1
2005
157
0.050
 Why?
MicroRNAs
1
2010
692
0.050
 Why?
Forecasting
3
2000
389
0.050
 Why?
Thrombocytopenia
3
2013
200
0.050
 Why?
Magnetic Resonance Imaging
1
2016
3566
0.050
 Why?
Mammaplasty
2
2016
105
0.050
 Why?
Up-Regulation
2
2017
843
0.050
 Why?
Activating Transcription Factor 4
1
2023
20
0.050
 Why?
Signal Transduction
5
2018
5079
0.050
 Why?
Proteasome Inhibitors
1
2023
46
0.050
 Why?
Proto-Oncogene Proteins c-mdm2
1
2023
65
0.050
 Why?
G(M2) Ganglioside
1
2022
1
0.050
 Why?
Injection Site Reaction
1
2022
3
0.050
 Why?
Cyclin E
1
2022
25
0.050
 Why?
Proteomics
1
2010
1111
0.050
 Why?
Clinical Trials, Phase III as Topic
2
2000
106
0.050
 Why?
Transcriptome
2
2023
971
0.050
 Why?
Treatment Failure
2
2001
356
0.050
 Why?
Luminescent Measurements
1
2003
76
0.050
 Why?
France
2
2019
33
0.050
 Why?
Oncogene Proteins
1
2022
59
0.050
 Why?
Ribose
1
2022
23
0.050
 Why?
Blood Transfusion, Autologous
2
1993
17
0.050
 Why?
Proteasome Endopeptidase Complex
1
2023
156
0.050
 Why?
Carbolines
1
2022
32
0.050
 Why?
Heterocyclic Compounds, 4 or More Rings
1
2022
20
0.050
 Why?
Adenosine Diphosphate
1
2022
79
0.050
 Why?
Career Choice
1
2024
219
0.050
 Why?
Class I Phosphatidylinositol 3-Kinases
1
2022
95
0.050
 Why?
Actuarial Analysis
2
1993
27
0.050
 Why?
Oncogenes
1
2022
116
0.050
 Why?
Tomography, X-Ray Computed
2
2015
2691
0.050
 Why?
Colony-Forming Units Assay
4
1996
91
0.040
 Why?
Cell Division
2
2001
794
0.040
 Why?
Gene Expression
2
2020
1502
0.040
 Why?
Carcinoembryonic Antigen
1
2001
39
0.040
 Why?
Phthalazines
1
2021
45
0.040
 Why?
Fellowships and Scholarships
1
2024
306
0.040
 Why?
Prospective Studies
5
2022
7604
0.040
 Why?
Transplantation Immunology
1
2000
34
0.040
 Why?
Clodronic Acid
1
2020
17
0.040
 Why?
Longitudinal Studies
2
2012
2844
0.040
 Why?
Extracellular Matrix
1
2024
528
0.040
 Why?
Phosphatidylinositol 3-Kinases
1
2022
366
0.040
 Why?
Progesterone
1
2002
254
0.040
 Why?
Ligands
1
2022
664
0.040
 Why?
Estradiol
2
2016
521
0.040
 Why?
Topoisomerase I Inhibitors
1
1999
17
0.040
 Why?
Thoracotomy
2
1997
75
0.040
 Why?
Polymerase Chain Reaction
1
2003
1062
0.040
 Why?
Hematopoietic Stem Cell Mobilization
1
1999
22
0.040
 Why?
Leucovorin
2
1997
81
0.040
 Why?
Bone Density Conservation Agents
1
2020
80
0.040
 Why?
Dendritic Cells
2
2000
483
0.040
 Why?
Mechlorethamine
1
2000
60
0.040
 Why?
Myelodysplastic Syndromes
1
2001
135
0.040
 Why?
Drug Resistance
1
1999
169
0.040
 Why?
Neoplasms, Experimental
1
2000
176
0.040
 Why?
Heterocyclic Compounds, 3-Ring
1
2019
32
0.040
 Why?
Receptors, Steroid
1
2019
50
0.040
 Why?
Cluster Analysis
2
2012
499
0.040
 Why?
Piperazines
1
2021
350
0.040
 Why?
Cell Cycle Proteins
1
2022
617
0.040
 Why?
Child
8
2022
21935
0.040
 Why?
Etanidazole
1
1998
1
0.040
 Why?
Leukemia
1
2001
240
0.040
 Why?
Enterocolitis, Pseudomembranous
1
1998
29
0.040
 Why?
Expectorants
1
1998
24
0.040
 Why?
Loss of Function Mutation
1
2018
46
0.040
 Why?
Aurora Kinase A
1
2018
56
0.040
 Why?
Nervous System
2
1997
67
0.040
 Why?
Cross-Over Studies
1
2020
564
0.040
 Why?
Statistics, Nonparametric
1
1999
431
0.040
 Why?
Retreatment
1
2018
72
0.040
 Why?
Mediastinum
1
1998
23
0.040
 Why?
Disease Susceptibility
1
2020
347
0.040
 Why?
Nausea
1
2018
111
0.040
 Why?
Epithelial Cell Adhesion Molecule
1
2017
13
0.040
 Why?
Myelin Basic Protein
1
2017
47
0.040
 Why?
ADAM17 Protein
1
2017
35
0.040
 Why?
Administration, Intravenous
1
2018
155
0.040
 Why?
Bromodeoxyuridine
1
2017
79
0.030
 Why?
Extremities
2
1989
131
0.030
 Why?
Watchful Waiting
1
2018
81
0.030
 Why?
Breast
1
2018
151
0.030
 Why?
SEER Program
1
2018
227
0.030
 Why?
Ganglia, Spinal
1
2017
77
0.030
 Why?
Medicare
1
2023
773
0.030
 Why?
Diarrhea
1
2018
184
0.030
 Why?
Cell Hypoxia
1
1998
226
0.030
 Why?
Double-Blind Method
1
2022
1993
0.030
 Why?
Thorax
1
1997
50
0.030
 Why?
Random Allocation
2
1988
353
0.030
 Why?
Coculture Techniques
1
2017
239
0.030
 Why?
Everolimus
1
2017
91
0.030
 Why?
Phosphoramide Mustards
1
2016
3
0.030
 Why?
Heterografts
1
2017
138
0.030
 Why?
Cyclohexanes
1
2016
21
0.030
 Why?
Cohort Studies
4
2001
5742
0.030
 Why?
Immunotoxins
1
1997
55
0.030
 Why?
Cells, Cultured
2
2017
4193
0.030
 Why?
Cytochrome P-450 CYP3A
1
2017
88
0.030
 Why?
Cell Survival
1
2000
1120
0.030
 Why?
Placebos
1
2016
199
0.030
 Why?
Ascorbic Acid
1
2017
177
0.030
 Why?
Gene Knockdown Techniques
1
2017
327
0.030
 Why?
Fluorescence Resonance Energy Transfer
1
2017
177
0.030
 Why?
Lymphoma, Large B-Cell, Diffuse
1
1998
123
0.030
 Why?
Carcinogenesis
1
2018
217
0.030
 Why?
Injections, Intravenous
2
1993
206
0.030
 Why?
Antineoplastic Agents, Immunological
1
2018
190
0.030
 Why?
Fertility Preservation
1
2016
49
0.030
 Why?
Blood Specimen Collection
1
1995
41
0.030
 Why?
Organoplatinum Compounds
3
1990
45
0.030
 Why?
Antidotes
1
1997
143
0.030
 Why?
Blood Component Transfusion
2
1994
84
0.030
 Why?
Digestive System
1
1995
27
0.030
 Why?
Animals, Newborn
1
2017
844
0.030
 Why?
Genetic Therapy
1
1997
297
0.030
 Why?
Transcriptional Activation
1
2017
378
0.030
 Why?
Mortality
1
1997
362
0.030
 Why?
Vincristine
1
1995
116
0.030
 Why?
Fertility
1
2016
160
0.030
 Why?
Interleukin-3
1
1994
25
0.030
 Why?
Hormones
1
2015
143
0.030
 Why?
Weight Gain
1
2018
519
0.030
 Why?
Kidney
2
1995
1468
0.030
 Why?
Diagnosis, Differential
1
2019
1483
0.030
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2017
250
0.030
 Why?
Pulmonary Fibrosis
3
1993
402
0.030
 Why?
Child, Preschool
6
2013
11074
0.030
 Why?
Leukocyte Count
5
1996
329
0.030
 Why?
Bacterial Infections
1
1996
250
0.030
 Why?
Tosyl Compounds
1
2014
15
0.030
 Why?
Odds Ratio
1
2017
1070
0.030
 Why?
Drug Discovery
1
2015
142
0.030
 Why?
Adipose Tissue
1
2018
635
0.030
 Why?
Hand-Foot Syndrome
1
2013
2
0.030
 Why?
Antioxidants
1
2017
584
0.030
 Why?
Protein Transport
1
2015
445
0.030
 Why?
Capecitabine
1
2013
45
0.030
 Why?
HEK293 Cells
1
2016
730
0.030
 Why?
Transplantation, Heterologous
1
2014
194
0.030
 Why?
Neoplasm Transplantation
1
2014
257
0.030
 Why?
Necrosis
1
2014
246
0.030
 Why?
Alternative Splicing
1
2015
229
0.030
 Why?
Erythropoietin
1
1994
95
0.030
 Why?
Cell Nucleus
1
2016
620
0.030
 Why?
Gene Silencing
1
2014
195
0.030
 Why?
Binding Sites
1
2016
1303
0.030
 Why?
Blood Cells
1
1993
40
0.030
 Why?
Cross-Sectional Studies
1
2024
5472
0.020
 Why?
CD24 Antigen
1
2012
20
0.020
 Why?
Nutritional Status
1
2015
350
0.020
 Why?
Recombinant Proteins
5
1997
1353
0.020
 Why?
Emergency Medical Services
1
2019
552
0.020
 Why?
Anemia
1
1994
170
0.020
 Why?
Sensitivity and Specificity
2
2000
1946
0.020
 Why?
Radionuclide Imaging
1
1992
118
0.020
 Why?
Diet, Reducing
1
2012
89
0.020
 Why?
Energy Intake
1
2015
485
0.020
 Why?
Psychotherapy, Group
1
2012
66
0.020
 Why?
Models, Biological
1
1999
1783
0.020
 Why?
Antigens, CD34
3
1996
88
0.020
 Why?
Hyaluronan Receptors
1
2012
102
0.020
 Why?
Counseling
1
2015
391
0.020
 Why?
Feasibility Studies
4
1998
956
0.020
 Why?
Surveys and Questionnaires
1
2024
5778
0.020
 Why?
Vascular Endothelial Growth Factor Receptor-1
1
2012
71
0.020
 Why?
Mice, SCID
1
2012
367
0.020
 Why?
Pandemics
1
2020
1639
0.020
 Why?
Tumor Burden
1
2012
309
0.020
 Why?
Fluorescent Antibody Technique
2
1990
390
0.020
 Why?
Logistic Models
1
2016
2074
0.020
 Why?
Biopsy, Needle
1
2011
189
0.020
 Why?
Mice, Inbred NOD
1
2012
601
0.020
 Why?
Disease Models, Animal
1
2021
4295
0.020
 Why?
Chromosomes, Human, Pair 9
1
1990
41
0.020
 Why?
Blast Crisis
1
1990
33
0.020
 Why?
Bilirubin
2
2002
97
0.020
 Why?
Colorado
1
2020
4565
0.020
 Why?
Chromosomes, Human, Pair 22
1
1990
45
0.020
 Why?
Immunoblotting
1
2010
308
0.020
 Why?
Health Status
1
2015
792
0.020
 Why?
Pemetrexed
1
2010
33
0.020
 Why?
Glutamates
1
2010
59
0.020
 Why?
Graft Survival
1
1993
535
0.020
 Why?
Gene Regulatory Networks
1
2012
305
0.020
 Why?
Magnetics
1
1990
48
0.020
 Why?
Antibodies, Anti-Idiotypic
1
1990
59
0.020
 Why?
Cytokines
1
1998
2085
0.020
 Why?
Urologic Diseases
1
1990
41
0.020
 Why?
Guanine
1
2010
79
0.020
 Why?
Kidney Diseases
2
1991
408
0.020
 Why?
Multiple Organ Failure
2
2002
128
0.020
 Why?
Real-Time Polymerase Chain Reaction
1
2010
346
0.020
 Why?
Health Behavior
1
2015
762
0.020
 Why?
RNA, Messenger
1
2017
2833
0.020
 Why?
Microspheres
1
1990
137
0.020
 Why?
Spinal Cord Neoplasms
1
1989
37
0.020
 Why?
Chromosome Aberrations
1
1990
156
0.020
 Why?
Cell Movement
1
2014
967
0.020
 Why?
Blood
1
1990
107
0.020
 Why?
Clone Cells
1
1990
265
0.020
 Why?
Pregnancy Trimester, Second
1
2009
80
0.020
 Why?
Promoter Regions, Genetic
1
2014
1250
0.020
 Why?
Central Nervous System Diseases
1
1990
69
0.020
 Why?
Hematuria
1
1989
12
0.020
 Why?
Vinblastine
2
2001
71
0.020
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
1990
122
0.020
 Why?
Lymphoma
1
1990
208
0.020
 Why?
Hypertension
1
2018
1295
0.020
 Why?
False Negative Reactions
1
1988
53
0.020
 Why?
Creatinine
1
1991
499
0.020
 Why?
Rats
1
2017
5647
0.020
 Why?
DNA Methylation
1
2014
643
0.020
 Why?
Pregnancy Trimester, First
1
2009
140
0.020
 Why?
Leukopenia
1
1988
31
0.020
 Why?
Niacinamide
1
2009
82
0.020
 Why?
Immunophenotyping
2
2000
318
0.020
 Why?
Apoptosis Regulatory Proteins
1
2009
188
0.020
 Why?
Neurons
1
2017
1590
0.020
 Why?
False Positive Reactions
1
1988
115
0.020
 Why?
Phenylurea Compounds
1
2009
97
0.020
 Why?
Histones
1
2014
636
0.020
 Why?
Hospitals, Veterans
1
2009
252
0.020
 Why?
Electrophoresis
1
1988
32
0.020
 Why?
Antigens, Differentiation
1
1988
83
0.020
 Why?
Transfection
1
2010
945
0.020
 Why?
Perilipin-1
1
2008
17
0.020
 Why?
Estrogen Receptor Modulators
1
2008
17
0.020
 Why?
Drug Interactions
1
1990
410
0.020
 Why?
Staining and Labeling
1
1988
150
0.020
 Why?
Macrophages
2
1995
1547
0.020
 Why?
S100 Proteins
1
2008
37
0.020
 Why?
Exercise Therapy
1
2012
443
0.020
 Why?
Antigens, Surface
1
1988
154
0.020
 Why?
Gene Expression Regulation
1
2017
2607
0.020
 Why?
Vimentin
1
1988
52
0.020
 Why?
Nervous System Diseases
1
1991
266
0.020
 Why?
Community Health Services
1
2009
227
0.020
 Why?
Central Nervous System
1
1990
258
0.020
 Why?
Androstadienes
1
2008
107
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2426
0.020
 Why?
Sarcoma, Kaposi
1
1988
81
0.020
 Why?
Bone Marrow Purging
2
1996
3
0.020
 Why?
Lung Diseases
2
1992
767
0.020
 Why?
Clinical Trials, Phase II as Topic
2
2000
76
0.020
 Why?
Health Knowledge, Attitudes, Practice
1
2015
1329
0.020
 Why?
Biomarkers
1
2018
4149
0.020
 Why?
Academic Medical Centers
1
2009
512
0.020
 Why?
Heart Diseases
1
1990
346
0.020
 Why?
Risk
2
2000
912
0.020
 Why?
Stem Cell Transplantation
1
2007
176
0.020
 Why?
Gastrointestinal Diseases
1
2008
209
0.020
 Why?
Phosphoproteins
1
2008
338
0.010
 Why?
Bevacizumab
1
2006
138
0.010
 Why?
Immunoglobulin G
1
1990
893
0.010
 Why?
Quality of Health Care
1
2009
642
0.010
 Why?
Body Mass Index
1
2012
2389
0.010
 Why?
Melanoma
2
1988
760
0.010
 Why?
Carrier Proteins
1
2008
771
0.010
 Why?
Ascites
1
2002
46
0.010
 Why?
Brain
1
2014
2668
0.010
 Why?
Phenotype
1
2010
3196
0.010
 Why?
Carcinoma, Lewis Lung
1
2001
15
0.010
 Why?
Carcinoma, Large Cell
1
2001
16
0.010
 Why?
Transplantation Conditioning
1
2002
170
0.010
 Why?
Hemorrhage
2
1998
722
0.010
 Why?
Phytohemagglutinins
1
2000
30
0.010
 Why?
CD4-CD8 Ratio
1
2000
22
0.010
 Why?
Hypersensitivity, Delayed
1
2000
28
0.010
 Why?
Lymphocyte Culture Test, Mixed
1
2000
50
0.010
 Why?
Drug Synergism
1
2001
382
0.010
 Why?
Microcomputers
1
2000
16
0.010
 Why?
Skin Tests
1
2000
101
0.010
 Why?
Louisiana
1
2000
29
0.010
 Why?
Graft vs Host Disease
1
2002
252
0.010
 Why?
Philadelphia
1
2000
49
0.010
 Why?
Immunoglobulins
1
2000
171
0.010
 Why?
Automation
1
2000
95
0.010
 Why?
Immunity
1
2000
143
0.010
 Why?
Personnel Selection
1
1980
78
0.010
 Why?
Lipopolysaccharide Receptors
1
1999
85
0.010
 Why?
Lung
1
1992
4060
0.010
 Why?
Marriage
1
1980
121
0.010
 Why?
Thalassemia
1
1998
7
0.010
 Why?
Interleukin-4
1
1999
216
0.010
 Why?
Heart Failure
1
1992
2236
0.010
 Why?
Receptors, Purinergic P1
1
1998
26
0.010
 Why?
Multicenter Studies as Topic
1
2000
310
0.010
 Why?
Microscopy, Fluorescence
1
2000
402
0.010
 Why?
Reference Values
1
2000
816
0.010
 Why?
Pilot Projects
2
1994
1710
0.010
 Why?
Acute Disease
1
2001
1007
0.010
 Why?
Infant, Newborn
1
2009
6079
0.010
 Why?
Filgrastim
1
1997
8
0.010
 Why?
Adenoviruses, Human
1
1996
27
0.010
 Why?
Killer Cells, Natural
1
2000
449
0.010
 Why?
Heparin
1
1998
261
0.010
 Why?
Lymphoma, B-Cell
1
1998
106
0.010
 Why?
Tissue Plasminogen Activator
1
1998
224
0.010
 Why?
Pregnancy
1
2009
6763
0.010
 Why?
Freezing
1
1996
90
0.010
 Why?
Lymphocyte Activation
1
2000
1142
0.010
 Why?
Lymphocyte Depletion
1
1996
135
0.010
 Why?
Genes, Reporter
1
1996
269
0.010
 Why?
Carcinoma, Squamous Cell
1
2001
683
0.010
 Why?
Drug Tolerance
1
1995
105
0.010
 Why?
Reticulocyte Count
1
1994
6
0.010
 Why?
Kidney Function Tests
1
1995
160
0.010
 Why?
Topotecan
1
1994
13
0.010
 Why?
Incidence
1
2001
2804
0.010
 Why?
Antigens, CD
1
1996
521
0.010
 Why?
Liver
1
2002
1943
0.010
 Why?
Registries
1
2002
2035
0.010
 Why?
Urinary Bladder Diseases
1
1993
19
0.010
 Why?
Glioblastoma
1
1996
345
0.010
 Why?
Heart
1
1997
655
0.010
 Why?
Boston
1
1993
91
0.010
 Why?
Flow Cytometry
1
1996
1178
0.010
 Why?
Chromatography, High Pressure Liquid
1
1995
597
0.010
 Why?
Iron
1
1994
313
0.010
 Why?
Palliative Care
1
1998
758
0.010
 Why?
Cell Line
1
1996
2847
0.010
 Why?
Immunologic Factors
1
1993
236
0.010
 Why?
Cystitis
1
1990
22
0.010
 Why?
Metabolic Clearance Rate
1
1989
115
0.000
 Why?
Introns
1
1990
258
0.000
 Why?
Platinum
1
1989
50
0.000
 Why?
Prostatic Neoplasms
1
1996
1043
0.000
 Why?
Drug Combinations
1
1990
343
0.000
 Why?
Brain Diseases
1
1990
141
0.000
 Why?
Macrophage-1 Antigen
1
1988
28
0.000
 Why?
Bone Marrow Examination
1
1988
5
0.000
 Why?
Platelet Count
1
1988
86
0.000
 Why?
Erythrocyte Count
1
1988
20
0.000
 Why?
Methods
1
1988
65
0.000
 Why?
Pelvic Neoplasms
1
1988
26
0.000
 Why?
Erythroblasts
1
1988
19
0.000
 Why?
Infant
1
2002
9465
0.000
 Why?
DNA Damage
1
1990
420
0.000
 Why?
Acute Kidney Injury
1
1995
815
0.000
 Why?
Fever
1
1988
306
0.000
 Why?
In Vitro Techniques
1
1988
1092
0.000
 Why?
Pneumonia
1
1992
639
0.000
 Why?
Statistics as Topic
1
1987
307
0.000
 Why?
Elias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (664) concept(s)
_
Co-Authors Expand Description
See all (60) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)